Skip to main content

SYSTEMATIC REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1485303
This article is part of the Research Topic The Influence of Cancer Cells, Tumor Microenvironment and their Crosstalk on Early Drug and Immunotherapy Developments View all articles

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal c a n c e r : a s y s t e m a t i c r e v i e w a n d m e t a -a n a l y s i s

Provisionally accepted
Dan d. Song Dan d. Song 1ShuFu Hou ShuFu Hou 2Ning Ma Ning Ma 3Bing Yan Bing Yan 2*Jing Gao Jing Gao 4*
  • 1 Department of Neurology, Shandong Provincial Third Hospital, Jinan, Shandong Province, China
  • 2 Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China
  • 3 Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China
  • 4 Shandong Provincial Third Hospital, Jinan, Shandong Province, China

The final, formatted version of the article will be published soon.

    were systematically searched for relevant studies. Outcomes including median progression-free survival (mPFS), median overall survival (mOS), overall response rate (ORR), disease control rate (DCR), treatment-related adverse events (TRAEs) and ≥grade 3 TRAEs were extracted for further analysis. The risk of bias was assessed by subgroup analysis.Results: 12 articles with 566 patients were identified and subjected to meta-analysis.With regard to survival analysis, the pooled mOS and mPFS were 6.66 months (95%CI 4.85-9.16) and 2.92 months (95%CI 2.23-3.83), respectively. In terms of tumor response, the pooled ORR and DCR were 21% (95%CI 6%-41%) and 49% (95%CI 27%-71%), respectively. The pooled AEs rate and ≥ grade 3 AEs rate were 94% (95%CI 86%-99%) and 44% (95%CI 30%-58%).PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors have shown promising clinical responses in the treatment of colorectal cancer (CRC). Although the incidence of adverse reactions is high, they are generally tolerable.

    Keywords: immune checkpoint inhibitors, colorectal cancer, Immunotherapy, PD-1, PD-L1, CTLA-4

    Received: 23 Aug 2024; Accepted: 15 Oct 2024.

    Copyright: © 2024 Song, Hou, Ma, Yan and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Bing Yan, Central Hospital Affiliated to Shandong First Medical University, Jinan, 271000, Shandong Province, China
    Jing Gao, Shandong Provincial Third Hospital, Jinan, Shandong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.